Jump to content

sec47

Member
  • Posts

    7
  • Joined

  • Last visited

Everything posted by sec47

  1. You maybe interested in this: https://www.newsshopper.co.uk/news/18951616.prolific-handbag-thief-jailed-traced-cctv/
  2. Hello all, I wish everyone the best of health but given the reality of the situation, I would like to spread awareness in the community for a NIHR (National Institute for Health Research) Covid home trial involving Southampton company Synairgen?s interferon beta-1a product. This is the most promising Covid therapeutic in development so far, with positive results from its Phase 2 study published in the Lancet journal on November 12th: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext In short, they are running a home and a hospital trial alongside Phase 3. To qualify for the home trial you need to be aged over 65 years old. or aged 50 and above and have other illnesses which makes you more susceptible to complications of COVID-19, with a confirmed SARS-CoV-2 infection. You can read more detail about it at their website https://www.covidtrialathome.com or you can contact the University of Southampton trial team directly at [email protected] or 0330 133 2870 (9am - 5pm, Mon - Fri). To qualify for the hospital trial you would need to be aged 18 or over and with a confirmed SARS-CoV-2 infection which has caused admission to hospital. See link on the NIHR site here: https://bepartofresearch.nihr.ac.uk/trial-details/trial-detail?trialId=9286&location=&distance= Please share if you think this could be helpful to any friends or family. Some extra links below from the NIHR about the Synairgen covid treatment below: https://www.nihr.ac.uk/news/covid-19-treatment-results-published-in-journal-ahead-of-nihr-supported-phase-3-trial-of-nebulised-interferon-beta/26186 https://www.nihr.ac.uk/documents/case-studies/delivering-commercial-urgent-public-health-research-synairgen/25079
Home
Events
Sign In

Sign In



Or sign in with one of these services

Search
×
    Search In
×
×
  • Create New...